+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceuticals Market in Germany 2023-2027

  • PDF Icon

    Report

  • 124 Pages
  • June 2023
  • Region: Germany
  • TechNavio
  • ID: 5847364
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Germany pharmaceuticals market is forecasted to grow by USD 21.44 bn during 2022-2027, accelerating at a CAGR of 6.25% during the forecast period. The report on the Germany pharmaceuticals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high investment in the pharmaceutical industry, the increasing geriatric population, and the growing number of M and A.

The Germany pharmaceuticals market is segmented as below:

By Distribution Channel

  • Pharmacy
  • Clinic

By Type

  • Prescription
  • Non-prescription
This study identifies the robust growth of e-commerce as one of the prime reasons driving the Germany pharmaceuticals market growth during the next few years. Also, the high demand for personalized medicines and increasing cases of chronic diseases will lead to sizable demand in the market.

The report on the Germany pharmaceuticals market covers the following areas:

  • Germany pharmaceuticals market sizing
  • Germany pharmaceuticals market forecast
  • Germany pharmaceuticals market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Germany pharmaceuticals market vendors that include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson Services Inc., MCM Klosterfrau Vertriebsgesellschaft mbH, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi, STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd.. Also, the Germany pharmaceuticals market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Country Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 06: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
  • Exhibit 07: Parent market
  • Exhibit 08: Market Characteristics
3 Market Sizing
3.1 Market definition
  • Exhibit 09: Offerings of vendors included in the market definition
3.2 Market segment analysis
  • Exhibit 10: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 11: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 12: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 13: Chart on Germany: Year-over-year growth 2022-2027 (%)
  • Exhibit 14: Data Table on Germany: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Pharmaceuticals market in Germany 2017 - 2021
  • Exhibit 15: Historic Market Size - Data Table on pharmaceuticals market in Germany 2017 - 2021 ($ billion)
4.2 Distribution Channel Segment Analysis 2017 - 2021
  • Exhibit 16: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ billion)
4.3 Type Segment Analysis 2017 - 2021
  • Exhibit 17: Historic Market Size - Type Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
  • Exhibit 18: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
  • Exhibit 19: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
  • Exhibit 20: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
  • Exhibit 21: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
  • Exhibit 22: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
  • Exhibit 23: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
  • Exhibit 24: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Distribution Channel
6.1 Market segments
  • Exhibit 25: Chart on Distribution Channel - Market share 2022-2027 (%)
  • Exhibit 26: Data Table on Distribution Channel - Market share 2022-2027 (%)
6.2 Comparison by Distribution Channel
  • Exhibit 27: Chart on Comparison by Distribution Channel
  • Exhibit 28: Data Table on Comparison by Distribution Channel
6.3 Pharmacy - Market size and forecast 2022-2027
  • Exhibit 29: Chart on Pharmacy - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 30: Data Table on Pharmacy - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 31: Chart on Pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibit 32: Data Table on Pharmacy - Year-over-year growth 2022-2027 (%)
6.4 Clinic - Market size and forecast 2022-2027
  • Exhibit 33: Chart on Clinic - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 34: Data Table on Clinic - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 35: Chart on Clinic - Year-over-year growth 2022-2027 (%)
  • Exhibit 36: Data Table on Clinic - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Distribution Channel
  • Exhibit 37: Market opportunity by Distribution Channel ($ billion)
  • Exhibit 38: Data Table on Market opportunity by Distribution Channel ($ billion)
7 Market Segmentation by Type
7.1 Market segments
  • Exhibit 39: Chart on Type - Market share 2022-2027 (%)
  • Exhibit 40: Data Table on Type - Market share 2022-2027 (%)
7.2 Comparison by Type
  • Exhibit 41: Chart on Comparison by Type
  • Exhibit 42: Data Table on Comparison by Type
7.3 Prescription - Market size and forecast 2022-2027
  • Exhibit 43: Chart on Prescription - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 44: Data Table on Prescription - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 45: Chart on Prescription - Year-over-year growth 2022-2027 (%)
  • Exhibit 46: Data Table on Prescription - Year-over-year growth 2022-2027 (%)
7.4 Non-prescription - Market size and forecast 2022-2027
  • Exhibit 47: Chart on Non-prescription - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 48: Data Table on Non-prescription - Market size and forecast 2022-2027 ($ billion)
  • Exhibit 49: Chart on Non-prescription - Year-over-year growth 2022-2027 (%)
  • Exhibit 50: Data Table on Non-prescription - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Type
  • Exhibit 51: Market opportunity by Type ($ billion)
  • Exhibit 52: Data Table on Market opportunity by Type ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
  • Exhibit 53: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Drivers, Challenges, and Trends
9.1 Market drivers
9.2 Market challenges
9.3 Impact of drivers and challenges
  • Exhibit 54: Impact of drivers and challenges in 2022 and 2027
9.4 Market trends
10 Vendor Landscape
10.1 Overview
10.2 Vendor landscape
  • Exhibit 55: Overview on Criticality of inputs and Factors of differentiation
10.3 Landscape disruption
  • Exhibit 56: Overview on factors of disruption
10.4 Industry risks
  • Exhibit 57: Impact of key risks on business
11 Vendor Analysis
11.1 Vendors covered
  • Exhibit 58: Vendors covered
11.2 Market positioning of vendors
  • Exhibit 59: Matrix on vendor position and classification
11.3 Abbott Laboratories
  • Exhibit 60: Abbott Laboratories - Overview
  • Exhibit 61: Abbott Laboratories - Business segments
  • Exhibit 62: Abbott Laboratories - Key news
  • Exhibit 63: Abbott Laboratories - Key offerings
  • Exhibit 64: Abbott Laboratories - Segment focus
11.4 AbbVie Inc.
  • Exhibit 65: AbbVie Inc. - Overview
  • Exhibit 66: AbbVie Inc. - Product/Service
  • Exhibit 67: AbbVie Inc. - Key news
  • Exhibit 68: AbbVie Inc. - Key offerings
11.5 AstraZeneca
  • Exhibit 69: AstraZeneca - Overview
  • Exhibit 70: AstraZeneca - Product/Service
  • Exhibit 71: AstraZeneca - Key news
  • Exhibit 72: AstraZeneca - Key offerings
11.6 Bayer AG
  • Exhibit 73: Bayer AG - Overview
  • Exhibit 74: Bayer AG - Business segments
  • Exhibit 75: Bayer AG - Key news
  • Exhibit 76: Bayer AG - Key offerings
  • Exhibit 77: Bayer AG - Segment focus
11.7 Boehringer Ingelheim International GmbH
  • Exhibit 78: Boehringer Ingelheim International GmbH - Overview
  • Exhibit 79: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 80: Boehringer Ingelheim International GmbH - Key news
  • Exhibit 81: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 82: Boehringer Ingelheim International GmbH - Segment focus
11.8 Fresenius SE and Co. KGaA
  • Exhibit 83: Fresenius SE and Co. KGaA - Overview
  • Exhibit 84: Fresenius SE and Co. KGaA - Business segments
  • Exhibit 85: Fresenius SE and Co. KGaA - Key news
  • Exhibit 86: Fresenius SE and Co. KGaA - Key offerings
  • Exhibit 87: Fresenius SE and Co. KGaA - Segment focus
11.9 GlaxoSmithKline Plc
  • Exhibit 88: GlaxoSmithKline Plc - Overview
  • Exhibit 89: GlaxoSmithKline Plc - Business segments
  • Exhibit 90: GlaxoSmithKline Plc - Key news
  • Exhibit 91: GlaxoSmithKline Plc - Key offerings
  • Exhibit 92: GlaxoSmithKline Plc - Segment focus
11.10 Johnson and Johnson Services Inc.
  • Exhibit 93: Johnson and Johnson Services Inc. - Overview
  • Exhibit 94: Johnson and Johnson Services Inc. - Business segments
  • Exhibit 95: Johnson and Johnson Services Inc. - Key news
  • Exhibit 96: Johnson and Johnson Services Inc. - Key offerings
  • Exhibit 97: Johnson and Johnson Services Inc. - Segment focus
11.11 MCM Klosterfrau Vertriebsgesellschaft mbH
  • Exhibit 98: MCM Klosterfrau Vertriebsgesellschaft mbH - Overview
  • Exhibit 99: MCM Klosterfrau Vertriebsgesellschaft mbH - Product/Service
  • Exhibit 100: MCM Klosterfrau Vertriebsgesellschaft mbH - Key offerings
11.12 Merck KGaA
  • Exhibit 101: Merck KGaA - Overview
  • Exhibit 102: Merck KGaA - Business segments
  • Exhibit 103: Merck KGaA - Key news
  • Exhibit 104: Merck KGaA - Key offerings
  • Exhibit 105: Merck KGaA - Segment focus
11.13 Novartis AG
  • Exhibit 106: Novartis AG - Overview
  • Exhibit 107: Novartis AG - Business segments
  • Exhibit 108: Novartis AG - Key offerings
  • Exhibit 109: Novartis AG - Segment focus
11.14 Pfizer Inc.
  • Exhibit 110: Pfizer Inc. - Overview
  • Exhibit 111: Pfizer Inc. - Product/Service
  • Exhibit 112: Pfizer Inc. - Key news
  • Exhibit 113: Pfizer Inc. - Key offerings
11.15 Sanofi
  • Exhibit 114: Sanofi - Overview
  • Exhibit 115: Sanofi - Business segments
  • Exhibit 116: Sanofi - Key news
  • Exhibit 117: Sanofi - Key offerings
  • Exhibit 118: Sanofi - Segment focus
11.16 STADA Arzneimittel AG
  • Exhibit 119: STADA Arzneimittel AG - Overview
  • Exhibit 120: STADA Arzneimittel AG - Business segments
  • Exhibit 121: STADA Arzneimittel AG - Key offerings
  • Exhibit 122: STADA Arzneimittel AG - Segment focus
11.17 Teva Pharmaceutical Industries Ltd.
  • Exhibit 123: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 124: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 125: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 127: Teva Pharmaceutical Industries Ltd. - Segment focus
12 Appendix
12.1 Scope of the report
12.2 Inclusions and exclusions checklist
  • Exhibit 128: Inclusions checklist
  • Exhibit 129: Exclusions checklist
12.3 Currency conversion rates for US$
  • Exhibit 130: Currency conversion rates for US$
12.4 Research methodology
  • Exhibit 131: Research methodology
  • Exhibit 132: Validation techniques employed for market sizing
  • Exhibit 133: Information sources
12.5 List of abbreviations
  • Exhibit 134: List of abbreviations
Exhibits:
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Country Market Characteristics
Exhibits 4: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Vendor Market Positioning
Exhibits 7: Parent market
Exhibits 8: Market Characteristics
Exhibits 9: Offerings of vendors included in the market definition
Exhibits 10: Market segments
Exhibits 11: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibits 12: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibits 13: Chart on Germany: Year-over-year growth 2022-2027 (%)
Exhibits 14: Data Table on Germany: Year-over-year growth 2022-2027 (%)
Exhibits 15: Historic Market Size - Data Table on pharmaceuticals market in Germany 2017 - 2021 ($ billion)
Exhibits 16: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ billion)
Exhibits 17: Historic Market Size - Type Segment 2017 - 2021 ($ billion)
Exhibits 18: Five forces analysis - Comparison between 2022 and 2027
Exhibits 19: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 20: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 21: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 22: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 23: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 24: Chart on Market condition - Five forces 2022 and 2027
Exhibits 25: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibits 26: Data Table on Distribution Channel - Market share 2022-2027 (%)
Exhibits 27: Chart on Comparison by Distribution Channel
Exhibits 28: Data Table on Comparison by Distribution Channel
Exhibits 29: Chart on Pharmacy - Market size and forecast 2022-2027 ($ billion)
Exhibits 30: Data Table on Pharmacy - Market size and forecast 2022-2027 ($ billion)
Exhibits 31: Chart on Pharmacy - Year-over-year growth 2022-2027 (%)
Exhibits 32: Data Table on Pharmacy - Year-over-year growth 2022-2027 (%)
Exhibits 33: Chart on Clinic - Market size and forecast 2022-2027 ($ billion)
Exhibits 34: Data Table on Clinic - Market size and forecast 2022-2027 ($ billion)
Exhibits 35: Chart on Clinic - Year-over-year growth 2022-2027 (%)
Exhibits 36: Data Table on Clinic - Year-over-year growth 2022-2027 (%)
Exhibits 37: Market opportunity by Distribution Channel ($ billion)
Exhibits 38: Data Table on Market opportunity by Distribution Channel ($ billion)
Exhibits 39: Chart on Type - Market share 2022-2027 (%)
Exhibits 40: Data Table on Type - Market share 2022-2027 (%)
Exhibits 41: Chart on Comparison by Type
Exhibits 42: Data Table on Comparison by Type
Exhibits 43: Chart on Prescription - Market size and forecast 2022-2027 ($ billion)
Exhibits 44: Data Table on Prescription - Market size and forecast 2022-2027 ($ billion)
Exhibits 45: Chart on Prescription - Year-over-year growth 2022-2027 (%)
Exhibits 46: Data Table on Prescription - Year-over-year growth 2022-2027 (%)
Exhibits 47: Chart on Non-prescription - Market size and forecast 2022-2027 ($ billion)
Exhibits 48: Data Table on Non-prescription - Market size and forecast 2022-2027 ($ billion)
Exhibits 49: Chart on Non-prescription - Year-over-year growth 2022-2027 (%)
Exhibits 50: Data Table on Non-prescription - Year-over-year growth 2022-2027 (%)
Exhibits 51: Market opportunity by Type ($ billion)
Exhibits 52: Data Table on Market opportunity by Type ($ billion)
Exhibits 53: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 54: Impact of drivers and challenges in 2022 and 2027
Exhibits 55: Overview on Criticality of inputs and Factors of differentiation
Exhibits 56: Overview on factors of disruption
Exhibits 57: Impact of key risks on business
Exhibits 58: Vendors covered
Exhibits 59: Matrix on vendor position and classification
Exhibits 60: Abbott Laboratories - Overview
Exhibits 61: Abbott Laboratories - Business segments
Exhibits 62: Abbott Laboratories - Key news
Exhibits 63: Abbott Laboratories - Key offerings
Exhibits 64: Abbott Laboratories - Segment focus
Exhibits 65: AbbVie Inc. - Overview
Exhibits 66: AbbVie Inc. - Product/Service
Exhibits 67: AbbVie Inc. - Key news
Exhibits 68: AbbVie Inc. - Key offerings
Exhibits 69: AstraZeneca - Overview
Exhibits 70: AstraZeneca - Product/Service
Exhibits 71: AstraZeneca - Key news
Exhibits 72: AstraZeneca - Key offerings
Exhibits 73: Bayer AG - Overview
Exhibits 74: Bayer AG - Business segments
Exhibits 75: Bayer AG - Key news
Exhibits 76: Bayer AG - Key offerings
Exhibits 77: Bayer AG - Segment focus
Exhibits 78: Boehringer Ingelheim International GmbH - Overview
Exhibits 79: Boehringer Ingelheim International GmbH - Business segments
Exhibits 80: Boehringer Ingelheim International GmbH - Key news
Exhibits 81: Boehringer Ingelheim International GmbH - Key offerings
Exhibits 82: Boehringer Ingelheim International GmbH - Segment focus
Exhibits 83: Fresenius SE and Co. KGaA - Overview
Exhibits 84: Fresenius SE and Co. KGaA - Business segments
Exhibits 85: Fresenius SE and Co. KGaA - Key news
Exhibits 86: Fresenius SE and Co. KGaA - Key offerings
Exhibits 87: Fresenius SE and Co. KGaA - Segment focus
Exhibits 88: GlaxoSmithKline Plc - Overview
Exhibits 89: GlaxoSmithKline Plc - Business segments
Exhibits 90: GlaxoSmithKline Plc - Key news
Exhibits 91: GlaxoSmithKline Plc - Key offerings
Exhibits 92: GlaxoSmithKline Plc - Segment focus
Exhibits 93: Johnson and Johnson Services Inc. - Overview
Exhibits 94: Johnson and Johnson Services Inc. - Business segments
Exhibits 95: Johnson and Johnson Services Inc. - Key news
Exhibits 96: Johnson and Johnson Services Inc. - Key offerings
Exhibits 97: Johnson and Johnson Services Inc. - Segment focus
Exhibits 98: MCM Klosterfrau Vertriebsgesellschaft mbH - Overview
Exhibits 99: MCM Klosterfrau Vertriebsgesellschaft mbH - Product/Service
Exhibits 100: MCM Klosterfrau Vertriebsgesellschaft mbH - Key offerings
Exhibits 101: Merck KGaA - Overview
Exhibits 102: Merck KGaA - Business segments
Exhibits 103: Merck KGaA - Key news
Exhibits 104: Merck KGaA - Key offerings
Exhibits 105: Merck KGaA - Segment focus
Exhibits 106: Novartis AG - Overview
Exhibits 107: Novartis AG - Business segments
Exhibits 108: Novartis AG - Key offerings
Exhibits 109: Novartis AG - Segment focus
Exhibits 110: Pfizer Inc. - Overview
Exhibits 111: Pfizer Inc. - Product/Service
Exhibits 112: Pfizer Inc. - Key news
Exhibits 113: Pfizer Inc. - Key offerings
Exhibits 114: Sanofi - Overview
Exhibits 115: Sanofi - Business segments
Exhibits 116: Sanofi - Key news
Exhibits 117: Sanofi - Key offerings
Exhibits 118: Sanofi - Segment focus
Exhibits 119: STADA Arzneimittel AG - Overview
Exhibits 120: STADA Arzneimittel AG - Business segments
Exhibits 121: STADA Arzneimittel AG - Key offerings
Exhibits 122: STADA Arzneimittel AG - Segment focus
Exhibits 123: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 124: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 125: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 126: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 127: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 128: Inclusions checklist
Exhibits 129: Exclusions checklist
Exhibits 130: Currency conversion rates for US$
Exhibits 131: Research methodology
Exhibits 132: Validation techniques employed for market sizing
Exhibits 133: Information sources
Exhibits 134: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the Germany pharmaceuticals market: Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson Services Inc., MCM Klosterfrau Vertriebsgesellschaft mbH, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi, STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the robust growth of e-commerce.'

According to the report, one of the major drivers for this market is the high investment in the pharmaceutical industry.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Fresenius SE and Co. KGaA
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • MCM Klosterfrau Vertriebsgesellschaft mbH
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Sanofi
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.